Evidence map›Paper›PMID 30023597›Full record

ArticleACS omega2017

Role of Biorelevant Dissolution Media in the Selection of Optimal Salt Forms of Oral Drugs: Maximizing the Gastrointestinal Solubility and in Vitro Activity of the Antimicrobial Molecule, Clofazimine.

Pauric Bannigan, Edel Durack, Conor Madden, Matteo Lusi, Sarah P Hudson

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Pauric BanniganDepartment of Chemical Sciences and Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
Edel DurackDepartment of Chemical Sciences and Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
Conor MaddenDepartment of Chemical Sciences and Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
Matteo LusiDepartment of Chemical Sciences and Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
Sarah P HudsonDepartment of Chemical Sciences and Synthesis and Solid State Pharmaceutical Centre, Bernal Institute, University of Limerick, Castletroy, Limerick V94 T9PX, Ireland.
University of Limerick · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clofazimine is an antimycobacterial agent that is routinely used for the treatment of leprosy. Clofazimine has also been shown to have high clinical potential for the treatment of many Gram-positive pathogens, including those that exhibit high levels of antibiotic resistance in the medical community. The use of clofazimine against these pathogens has largely been limited by the inherently poor water solubility of the drug substance. In this work, the possibility of repurposing and reformulating clofazimine to maximize its clinical potential is investigated. To achieve this, the potential of novel salt forms of clofazimine as supersaturating drug-delivery vehicles to enhance the aqueous solubility and gastrointestinal solubility of the drug substance was explored. The solution properties of seven novel salt forms, identified during an initial screening process, were examined in water and in a gastrointestinal-like media and were compared and contrasted with those of the free base, clofazimine, and the commercial formulation of the drug, Lamprene. The stability of the most promising solid forms was tested, and their bioactivity against

Identifiers

PMID30023597
PMCPMC6045360
OpenAlexW2773638645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.